Sera Prognostics (NASDAQ:SERA) Posts Earnings Results, Beats Estimates By $0.03 EPS

Sera Prognostics (NASDAQ:SERA) posted its quarterly earnings results on Thursday. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.03, FiscalAI reports. Sera Prognostics had a negative net margin of 34,343.16% and a negative return on equity of 42.41%. The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.10 million.

Sera Prognostics Stock Up 0.3%

NASDAQ SERA opened at $2.96 on Friday. The stock has a market capitalization of $111.50 million, a PE ratio of -3.84 and a beta of 0.97. Sera Prognostics has a 12-month low of $1.37 and a 12-month high of $9.13. The company has a 50 day moving average price of $3.15 and a two-hundred day moving average price of $2.68.

Insider Buying and Selling at Sera Prognostics

In related news, CEO Zhenya Lindgardt sold 21,158 shares of Sera Prognostics stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $3.15, for a total value of $66,647.70. Following the completion of the sale, the chief executive officer owned 811,136 shares of the company’s stock, valued at approximately $2,555,078.40. The trade was a 2.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last quarter, insiders have sold 52,627 shares of company stock worth $159,853. 13.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Sera Prognostics

Institutional investors have recently bought and sold shares of the stock. Captrust Financial Advisors boosted its stake in shares of Sera Prognostics by 20.0% during the 2nd quarter. Captrust Financial Advisors now owns 602,277 shares of the company’s stock worth $1,668,000 after acquiring an additional 100,366 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Sera Prognostics by 4.6% during the 3rd quarter. Vanguard Group Inc. now owns 1,217,190 shares of the company’s stock worth $3,725,000 after buying an additional 54,008 shares during the period. Corient Private Wealth LLC boosted its holdings in shares of Sera Prognostics by 73.9% during the 2nd quarter. Corient Private Wealth LLC now owns 100,000 shares of the company’s stock worth $277,000 after buying an additional 42,500 shares during the period. Qube Research & Technologies Ltd acquired a new position in Sera Prognostics in the 2nd quarter valued at $92,000. Finally, Two Sigma Investments LP bought a new position in Sera Prognostics in the 3rd quarter worth $97,000. 54.64% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sera Prognostics in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Sera Prognostics from a “sell” rating to a “hold” rating in a research note on Saturday, October 25th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.